Galectin Therapeutics (NASDAQ: GALT) swaps $105.8M debt for stock
Rhea-AI Filing Summary
Galectin Therapeutics Inc. converted approximately $105.8 million of debt owed to its chairman and largest stockholder, Richard E. Uihlein, into equity effective July 31, 2026. The conversion eliminated $91.0 million of principal and about $14.8 million of accrued interest arising from five line-of-credit facilities.
In exchange, the company issued 34,376,167 shares of common stock at a blended average conversion price of about $3.07 per share, using the Section 3(a)(9) exemption from registration. After the transaction, 100,849,644 common shares and 197,500 Series A Voting Preferred shares were outstanding, and Mr. Uihlein beneficially holds roughly 44.3% of voting power, or 49.3% including warrants. A separate $10 million supplemental credit facility from December 2025 remains undrawn and available, and the company is obligated to register the resale of the new shares within 180 days of conversion.
Positive
- $105.8 million of principal and accrued interest under insider line-of-credit notes was converted into equity, eliminating this debt obligation and removing a large interest-bearing liability from the capital structure.
- A separate December 2025 supplemental credit facility for up to $10,000,000 remains undrawn and fully available, preserving additional liquidity capacity after the debt-to-equity conversion.
Negative
- Issuance of 34,376,167 new shares to the chairman increased the common share count and left him with approximately 44.3% actual voting power and 49.3% including warrants, concentrating control with a single stockholder.
Filing Explained
Effective
8-K Event Classification
Item 3.02 — Unregistered Sales of Equity Securities
1 item
Item 3.02
Unregistered Sales of Equity Securities
Securities
The company sold equity securities in a private placement or other unregistered transaction.
Key Figures
Total debt converted: $105.8 million
Principal eliminated: $91.0 million
Accrued interest eliminated: $14.8 million
+5 more
8 metrics
Total debt converted
$105.8 million
Aggregate principal and accrued interest exchanged for equity under five credit facilities
Principal eliminated
$91.0 million
Aggregate principal of convertible promissory notes converted to common stock
Accrued interest eliminated
$14.8 million
Approximate accrued interest on notes converted to common stock
Shares issued in conversion
34,376,167 shares
Common stock issued to Richard E. Uihlein upon conversion of all outstanding notes
Shares outstanding post-conversion
100,849,644 shares
Common stock outstanding as of July 31, 2026 after conversion
Blended conversion price
$3.07 per share
Approximate blended average conversion price across all converted notes
Undrawn credit facility
$10,000,000
December 19, 2025 Supplemental Line of Credit Agreement remaining available
Chairman voting power incl. warrants
49.3%
Beneficial voting power including shares issuable upon exercise of outstanding warrants
Key Terms
convertible promissory notes, Section 3(a)(9), registration rights, beneficially owns, +1 more
5 terms
convertible promissory notes financial
"upon the conversion of all outstanding convertible promissory notes"
A convertible promissory note is a loan a company takes that can later be turned into shares instead of being paid back in cash; think of lending money now in exchange for a voucher that can become ownership later. Investors care because it mixes credit risk and potential ownership upside—it can protect lenders if a company struggles while also diluting existing shareholders when converted, affecting future share value and investor returns.
Section 3(a)(9) regulatory
"exempt from registration under the Securities Act pursuant to Section 3(a)(9)"
Section 3(a)(9) is a provision of U.S. securities law that exempts certain exchanges of an issuer’s own securities with its existing holders from the usual public registration rules, typically when the swap doesn’t involve a public offering or outside buyers. For investors, it matters because such exchanges can change who holds what, affect dilution and liquidity, and may occur with less public disclosure than a registered sale — think of it like swapping old coupons for new ones behind the scenes rather than selling them in a public marketplace.
registration rights regulatory
"pursuant to the registration rights provisions in the line of credit agreements"
Registration rights are contractual promises that let investors require a company to file paperwork with securities regulators so those investors can sell their shares to the public. They matter because they create a path to liquidity and an exit plan—without them, investors may be stuck holding shares for a long time. Think of them like a reserved ticket that guarantees access to a public marketplace when the holder is ready to sell.
beneficially owns financial
"Mr. Uihlein beneficially owns approximately 44.3% of the outstanding voting power"
Beneficially owns means a person or entity enjoys the economic benefits and control of a security even if the legal title or registration is held in another name. Think of it like having the keys and profits from a car that is registered to a friend: you use it, benefit from it, and make decisions about it even though the official paperwork lists someone else. For investors, this matters because it reveals who truly controls shares, affects voting power, potential conflicts of interest, and regulatory disclosure obligations.
Fast Track designation medical
"belapectin has Fast Track designation by the U.S. Food and Drug Administration"
Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What debt-to-equity transaction did Galectin Therapeutics (GALT) complete on July 31, 2026?
Galectin converted approximately $105.8 million of debt owed to Chairman Richard E. Uihlein into equity. This represented $91.0 million in principal and about $14.8 million in accrued interest under five line-of-credit note facilities.
What is Richard E. Uihlein’s ownership and voting power in Galectin Therapeutics (GALT) after the conversion?
After the conversion, Richard E. Uihlein beneficially owns about 44.3% of Galectin’s outstanding voting power. When including shares issuable upon exercise of his warrants, his beneficial voting power is approximately 49.3%, giving him significant influence over shareholder votes.
What unused credit capacity does Galectin Therapeutics (GALT) have after the conversion?
Galectin retains an undrawn $10,000,000 Supplemental Line of Credit Agreement dated December 19, 2025. No amounts have been borrowed and no convertible notes issued under this facility, which remains outstanding and available on its existing terms.